NHS to Offer Wegovy to Over a Million People to Cut Heart Attack and Stroke Risk
The NHS in England has announced that a GLP-1 drug called Wegovy (semaglutide) will be made available within months for secondary prevention of cardiovascular disease. Around 1.2 million eligible patients (with a history of cardiovascular events and a BMI of 27 or higher) will be able to access this once-weekly injection via the NHS to help reduce their risk of future heart attacks and strokes.